Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled to take place from September 9-11, 2024 in New York City.
Longeveron's presentation is set for Tuesday, September 10, 2024, from 5:00 – 5:30 p.m. ET. Investors and interested parties can access the webcast through the "Events and Presentations" section of the company's website. A replay of the presentation will be available for 180 days following the conference.
This conference provides Longeveron with an opportunity to showcase its progress in developing cellular therapies for life-threatening and chronic aging-related conditions to a global investment audience.
Longeveron Inc. (NASDAQ: LGVN), una società biotecnologica nel settore delle medicine rigenerative in fase clinica, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. L'evento si svolgerà dal 9 all'11 settembre 2024 a New York.
La presentazione di Longeveron è prevista per martedì 10 settembre 2024, dalle 17:00 alle 17:30 ET. Gli investitori e le parti interessate possono accedere al webcast attraverso la sezione
Longeveron Inc. (NASDAQ: LGVN), una compañía de biotecnología especializada en medicina regenerativa en fase clínica, ha anunciado su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright. El evento está programado para llevarse a cabo del 9 al 11 de septiembre de 2024 en la ciudad de Nueva York.
La presentación de Longeveron está programada para el martes 10 de septiembre de 2024, de 5:00 a 5:30 p.m. ET. Los inversores y las partes interesadas pueden acceder al webcast a través de la sección de
롱기버론 Inc. (NASDAQ: LGVN), 임상 단계 재생 의학 생명공학 회사,는 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕에서 열립니다.
롱기버론의 발표는 2024년 9월 10일 화요일, 오후 5시부터 5시 30분까지 (동부 표준시)로 예정되어 있습니다. 투자자 및 관심 있는 분들은 회사 웹사이트의
Longeveron Inc. (NASDAQ: LGVN), une entreprise de biotechnologie de médecine régénérative en phase clinique, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'événement est prévu du 9 au 11 septembre 2024 à New York.
La présentation de Longeveron est fixée au mardi 10 septembre 2024, de 17h00 à 17h30 (ET). Les investisseurs et les personnes intéressées peuvent accéder à la diffusion en direct via la section
Longeveron Inc. (NASDAQ: LGVN), ein biotechnologisches Unternehmen für regenerative Medizin in der klinischen Phase, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Die Veranstaltung findet vom 9. bis 11. September 2024 in New York City statt.
Die Präsentation von Longeveron ist für Dienstag, den 10. September 2024, von 17:00 bis 17:30 Uhr ET angesetzt. Investoren und Interessierte können über den Abschnitt „Veranstaltungen und Präsentationen“ auf der Website des Unternehmens auf das Webcast zugreifen. Eine Wiederholung der Präsentation wird für 180 Tage nach der Konferenz zur Verfügung stehen.
Diese Konferenz bietet Longeveron die Möglichkeit, seine Fortschritte in der Entwicklung zellulärer Therapien für lebensbedrohliche und chronische alterungsbedingte Erkrankungen einem globalen Investitionspublikum zu präsentieren.
- None.
- None.
MIAMI, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City.
Details for the Company’s presentation:
| Date: | Tuesday, September 10, 2024 | |
| Time: | 5:00 – 5:30 p.m. ET |
The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 180 days following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Aging-related Frailty. Lomecel-B™ development programs have received five distinct and important U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
When is Longeveron (LGVN) presenting at the H.C. Wainwright Global Investment Conference?
Where can I watch Longeveron's (LGVN) presentation at the H.C. Wainwright conference?
How long will the replay of Longeveron's (LGVN) conference presentation be available?
What type of company is Longeveron (LGVN)?
